Navigation Links
Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBI's Early Commercialization Conference
Date:2/19/2008

RALEIGH, N.C., Feb. 19 /PRNewswire/ -- Campbell Alliance, the leading management consulting firm specializing in the pharmaceutical and biotech industry, today announced that executives from its Brand Management and Managed Markets practices will present at the 4th Annual Forum on Early Stage Product Development and Commercialization Strategies for the Bio/Pharmaceutical Industry hosted by the Center for Business Intelligence (CBI). The conference will be held February 25-26, 2008, at the Doubletree Hotel in Philadelphia, Pennsylvania.

Tom Luginbill, Vice President, and Philip Vorhies, Practice Executive, of the firm's Brand Management practice will present a workshop titled "Comprehensive Commercial Planning for Product Launch" at 3:30 pm on February 25. They will provide a comprehensive understanding of each stage of pre- launch commercial planning and identify the key deliverables for each stage. They will also discuss strategies for managing the logistics of a launch. In addition, the workshop will feature an interactive working session, during which delegates will collaborate to determine the timing of each commercial planning stage and logistics-related activity during this critical phase of a product's life cycle.

Tom Luginbill currently leads the Brand Management practice's Central region operations, but he has spent the majority of his career in the industry. In the course of his 20-year career, he has had a wide variety of commercial roles, including Sales Representative, Marketing Director, and Regional Sales Director. He also served as the Vice President of Commercial Strategy at GlaxoSmithKline, where he was responsible for the worldwide commercial development of the company's antibiotic portfolio.

Philip Vorhies brings years of experience in the pharmaceutical industry and management consulting to his work with Campbell Alliance. Mr. Vorhies has in-depth experience with launch management, life cycle planning, and commercial
'/>"/>

SOURCE Campbell Alliance
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Campbell Alliance Brand Management Practice to Discuss Managing Launch Logistics at the EyeForPharma Oncology Summit
2. Campbell Alliance Trade and Distribution Practice to Chair CBI 3rd Annual Fee for Service and EDI Data Management Conference
3. Campbell Alliance Launches New Practice Area Focused on Trade and Distribution
4. Campbell Alliance Business Development Practice to Moderate Two Workshops at LES Annual Meeting in Vancouver
5. Campbell Alliance Named Best Place to Work by Triangle Business Journal
6. Campbell Alliance Managed Markets Practice to Take Leadership Role at CBIs Formulary and Reimbursement Conference
7. Campbell Alliance to Moderate Senior-Level Panel Discussion at Windhover Pharmaceutical Strategic Alliances Conference
8. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
9. Siemens and National Jewish Medical and Research Center Form Strategic Alliance to Advance Shared Vision of Personalized Medicine
10. HOYA ConBio and The Hornbrook Group Announce Expanded Alliance
11. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...ael, December 2 Gamida Cell announ...inical (animal study) safety and,efficacy of a gen...eill,Cornell Medical College and Gamida Cell. The ...ias such as Cooley,s Anemia. , Gamida Cel..., ex vivo,populations of stem/progenitor cells. T...
(Date:12/2/2009)...wswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ:...armaceutical company focused on endocrine therapy ...nd Drug Administration (FDA) has granted Fast Trac...nhibitor compound, perifosine (KRX-0401), for the ... Keryx Biopharmaceuticals, Inc. ("Keryx") ( KERX),...
(Date:12/1/2009)...olomon announced that he has joined Carolina Eyeca...ite at www.DrKerrySolomon.com , which was develop...proven LASIK, lens implant, and cataract surgery e...is substantial contributions to improving vision c...K Surgeons, which screens LASIK surgeons based upo...
(Date:12/1/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Emerging Clinical Trial Locations - E...althcare and regulatory environment ,, http:/...rial-Locations---Eastern-Europe-Market-dynamics-an...nt.html ,, Over the last decade pharmaceutical...
Breaking Biology Technology:Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 2Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 3Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 4Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 5Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 6Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 7Reportlinker Adds Emerging Clinical Trial Locations - Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment 8
...L, Inc. (Amex:,ADL), headquartered in Tustin, Cali...ilin, China, through its wholly owned subsidiary J... biopharma company that,together with JPI, engages...proprietary pharmaceutical, health care and diagno...I,s subsidiary, JJB, won a supply contract,for the...
... Pharmaceuticals,Inc. (Amex: ANX ), a biopharmace... commercializing proprietary product candidates fo... announced today that Evan M. Levine, the,company,... position as,Chief Executive Officer and President...eptember 2006., The company also announced that J...
...re-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NA...ceutical and,medical device company, is scheduled ...eutical, Biotechnology and Medical Device Conferen...NY., Dr. William Hunter, Angiotech,s President an...on Tuesday, February 5, at the Grand Hyatt New,Yor...
Other Biology Technology:AMDL Wins Chinese Military Supply Agreement for Its Domperidone Product for up to $6.6 Million 2ADVENTRX Announces Consolidation of Clinical and Management Positions 2ADVENTRX Announces Consolidation of Clinical and Management Positions 3
(Date:12/1/2009)...ner of the 2009 Inserm Grand Prix., Every year s...aying tribute to outstanding,work performed in it...ts, Inserm intends to,demonstrate the diversity a...ical, medical and,health research, and the creati...t and,drive this research each day. The Inserm 20...
(Date:12/1/2009)...t-and-run attacks by sharks can be solved with a n...nique chomp they put on their victims, according t...ert. , In a method analogous to analyzing human ...by precisely comparing shark bites to the jaws and...ess, director of the International Shark Attack Fi...
(Date:12/1/2009)...onash University-led international research team h... of the next generation of solar cells. , Scient...olleagues from the universities of Wollongong and ...d solar cells with a three-fold increase in energy...ported tandem dye-sensitised solar cells. , Lea...
Breaking Biology News(10 mins):Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 2Yehezkel Ben-Ari, winner of the 2009 INSERM Grand Prix 3New forensic technique gives clues about sharks from bite damage 2New forensic technique gives clues about sharks from bite damage 3Innovation puts next-generation solar cells on the horizon 2Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 1Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 2Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 3Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 4Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 5Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 6Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once Daily Vyvanse 28R 29 28lisdexamfetamine dimesylate 29 CII Prov 13143 7Abbott HIV Test Demonstrates Earlier Disease Detection 13141 1Abbott HIV Test Demonstrates Earlier Disease Detection 13141 2Abbott HIV Test Demonstrates Earlier Disease Detection 13141 3Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 1Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 2Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 3Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 4Quigley Corporation Announces Final Results of Quigley Pharmas Phase IIb Study 52380 5
...ational team of Mayo Clinic-led researchers is fir...he measles virus into a therapeutic killer that hu...ells only. Their research findings appear as an ad... , The researchers harnessed the viral trait for ...cted the virus to attack diseased, rather than hea...
...ing the value of good prenatal care, new research ...ve vulnerability that appears later during stress ...y of Colorado at Boulder have reported that rats w...dn,t learn as well as adult rats who were not infe... The research is in February,s Behavioral Neurosci...
...ng animals, Johns Hopkins researchers have discove...eviate HIV,s negative effects on the brain and cen...n though antiretroviral therapy controls the virus...ith simian immunodeficiency virus (SIV), a very cl...had less damage to brain cells, less brain inflamm...
Other Biology News:Mayo Clinic Researchers Create 'Obedient Virus'; First Step To Use Measles Virus Against Cancer 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 2Rats infected as newborns grew up vulnerable to memory problems during an immune challenge 3Antibiotic might fight HIV-induced neurological problems 2Antibiotic might fight HIV-induced neurological problems 3
Yeast Nitrogen Base from Invitrogen
Streptavidin, PE conjugated/tagged from Invitrogen
Rabbit Anti-Human PVRL2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
GIBCO AmnioMAX-C100 Basal Medium liquid from Invitrogen
Biology Products: